Holen Sie sich die Stockscreener-App
1.45
2.11%
0.03
Schlusskurs vom Vortag:
$1.42
Offen:
$1.48
24-Stunden-Volumen:
1.29M
Relative Volume:
1.05
Marktkapitalisierung:
$129.77M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-19.58M
KGV:
-5.6267
EPS:
-0.2577
Netto-Cashflow:
$-20.25M
1W Leistung:
+20.83%
1M Leistung:
+33.03%
6M Leistung:
-3.33%
1J Leistung:
+417.86%
1-Tages-Spanne:
$1.39
$1.50
1-Wochen-Bereich:
$1.185
$1.50
52-Wochen-Spanne:
$0.25
$3.83
Cognition Therapeutics Inc Stock (CGTX) Company Profile
Firmenname
Cognition Therapeutics Inc
Sektor
Branche
Telefon
412-481-2210
Adresse
2500 WESTCHESTER AVE, PURCHASE
Compare CGTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CGTX
Cognition Therapeutics Inc
|
1.45 | 129.77M | 0 | -19.58M | -20.25M | -0.2577 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-19 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2024-07-30 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-11-03 | Eingeleitet | B. Riley Securities | Buy |
| 2021-11-03 | Eingeleitet | Oppenheimer | Outperform |
Cognition Therapeutics Inc Aktie (CGTX) Neueste Nachrichten
Cognition Therapeutics Advances Zervimesine Toward Phase 3 DLB Trial - TipRanks
Cognition Therapeutics elects directors and ratifies auditor at annual meeting - Investing.com UK
Cognition Therapeutics elects directors and ratifies auditor at annual meeting By Investing.com - Investing.com Nigeria
Cognition Therapeutics Shareholders Elect Directors, Ratify Auditor - TipRanks
Shareholders of Cognition Therapeutics (CGTX) reelect directors and ratify Ernst & Young - Stock Titan
Cognition Therapeutics Inc (CGTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cognition Therapeutics Inc (CGTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cognition Therapeutics Inc (CGTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cognition Therapeutics Inc (CGTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cognition Therapeutics Inc (CGTX) Institutional Confidence - TradingKey
Cognition Therapeutics Inc (CGTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cognition Therapeutics Inc (CGTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cognition Therapeutics Receives Patent Allowance for Polymorphic Crystalline Form of Zervimesine - marketscreener.com
Cognition Therapeutics receives patent allowance for zervimesine By Investing.com - Investing.com South Africa
Alzheimer's and DLB drug CT1812 gets new patent shield into 2045 - Stock Titan
Cognition Therapeutics Inc (CGTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CGTX Q1 2026 Earnings: EPS Beat Exceeds Estimates; Cash Runway Supports Alzheimer’s ProgramsShare Repurchase Impact - newsline.com
Cognition Therapeutics (CGTX) Rises 5.26% as Shares Approach Key ResistanceBullish Pattern Stocks - newsline.com
Cognition Therapeutics (CGTX) Gets a Buy from H.C. Wainwright - The Globe and Mail
Cognition Therapeutics (CGTX) Slips 5% as Biotech Momentum FadesIndex Put Call - newsline.com
Cognition Therapeutics advances zervimesine toward registrational DLB psychosis program; cash into Q2 2027 - TradingView
[8-K] COGNITION THERAPEUTICS INC Reports Material Event - Stock Titan
Cognition Therapeutics Reviews Phase 2 Results With FDA - asatunews.co.id
Cognition Therapeutics Meets FDA and Reduces First Quarter Net Loss - HarianBasis.co
Is Cognition Therapeutics, Inc. (CGTX) Moving Closer to a Registrational Trial in Dementia With Lewy Bodies? - Insider Monkey
Cognition Therapeutics, Inc. CEO Lisa Ricciardi to Present at June Financial Conferences on DLB Psychosis Registration Program - Quiver Quantitative
Cognition Therapeutics Participating in Upcoming Investor Conferences - The Manila Times
CGTX Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Progress for Alzheimer’s PipelineFull Year Guidance - newsline.com
Cognition Therapeutics Inc. (CGTX) Q1 2026 Earnings: Narrower‑than‑Expected Loss as Clinical Progress ContinuesPreliminary Results - newsline.com
Cognition Therapeutics (CGTX) Edges Lower as Stock Hovers Near Key SupportPrice Momentum Stocks - The Legal Advocate
Cognition Therapeutics (CGTX) Holds Steady Near Key Support LevelRatio Spread Trade - newsline.com
CGTX News | COGNITION THERAPEUTICS INC (NASDAQ:CGTX) - ChartMill
CGTX Stock Price, Quote & Chart | COGNITION THERAPEUTICS INC (NASDAQ:CGTX) - ChartMill
Cognition Therapeutics (CGTX) Slides 1.59% as Biotech Sector Headwinds PersistSentiment Shift - The Legal Advocate
Cognition Therapeutics Inc. (CGTX) Slips Modestly as Stock Hovers Near Support ZoneBPI Bear Confirmed - The Legal Advocate
CGTX Q1 2026 Earnings: Narrower Loss Exceeds Estimates as Pre-Revenue Biotech Advances PipelineFree Cash Flow Trends - Newser
CGTX Q1 2026 Earnings: Cognition Therapeutics Reports Narrower-Than-Expected Loss, No Revenue YetTech Earnings Analysis - newsline.com
Cognition Therapeutics Inc. (CGTX) Q1 2026 Earnings: Narrower Loss on Lower Expenses, No Revenue ReportedGuidance Revision Trend - The Legal Advocate
Cognition Therapeutics Advances Zervimesine (CT1812) Toward Registrational Trial for Dementia with Lewy Bodies Psychosis After Positive FDA Meeting - Minichart
Cognition Therapeutics discusses FDA meeting on DLB drug trial By Investing.com - Investing.com South Africa
Cognition Therapeutics discusses FDA meeting on DLB drug trial - Investing.com
Cognition Therapeutics Advances Zervimesine Toward Late-Stage DLB Trial - TipRanks
Cognition Therapeutics, Inc. Reports Positive FDA Meeting on Zervimesine Development for Dementia with Lewy Bodies Psychosis - Quiver Quantitative
Cognition Therapeutics completes FDA meeting, sees path for registrational DLB psychosis program - TradingView
Cognition Therapeutics (CGTX) outlines FDA path for zervimesine DLB psychosis trial - Stock Titan
FDA, Cognition discuss next trial for Lewy body dementia psychosis drug - Stock Titan
Cognition Therapeutics Completes Meeting with FDA for - GlobeNewswire
Cognition Therapeutics, Inc.Common Stock (NQ: CGTX - The Chronicle-Journal
CGTX Should I Buy - Intellectia AI
TradingKey - TradingKey
Cognition Therapeutics receives donation to extend DLB program By Investing.com - Investing.com Australia
Finanzdaten der Cognition Therapeutics Inc-Aktie (CGTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):